Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Flavio Crameri"'
Autor:
Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina de Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus van Dongen, Ekkehard Moessner, Pablo Umaña
Publikováno v:
OncoImmunology, Vol 6, Iss 3 (2017)
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://doaj.org/article/a319ded80cfa47ca96224b37437a82ff
Autor:
Nicolini Valeria G, Amandine Ongaro, Armando G. Burgos-Rodriguez, Christopher T. Whitlow, Wei Xu, Peter N. Morcos, Peter Brünker, Sara Colombetti, Martina Carola Birk, Michael Hettich, Sabine Lang, Christine Küttel, Stella Tournaviti, Tanja Fauti, Pablo Umana, Preethi Latha Bhavani Mohan, Sylvia Herter, Thomas von Hirschheydt, Alfred Zippelius, Johannes Sam, Christina Claus, Marina Bacac, J. Mark Cline, Tamara Hüsser, Mario Perro, Reto Gianotti, Kiran Kumar Solingapuram Sai, Viola Heinzelmann-Schwarz, Matthias E. Lauer, Maurizio Ceppi, Christian Klein, Anna Maria Giusti, Anne Freimoser-Grundschober, Hofer Thomas U, Ralf Hosse, Stanford Chen, Maria Amann, Volker Teichgräber, Rosmarie Albrecht, John Challier, Christophe Prince, Ekkehard Mössner, Jörg Benz, Claudia Ferrara, David L. Caudell, Philippe Ringler, Franziska Uhlenbrock, Sandra Grau-Richards, Henning Stahlberg, Victor Levitsky, Michael Molhoj, Catherine Joseph, Wouter H. P. Driessen, Gregory O. Dugan, Sarah Diggelmann, Ramona Schlenker, Flavio Crameri
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti–4-1BB antibodies, although effective preclinically, has not advanced to phase 3 trials because
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042e824bda5fbaedcbd140cabc14302f
https://europepmc.org/articles/PMC7181714/
https://europepmc.org/articles/PMC7181714/
Autor:
Flavio Crameri, Edit Tarcsa, Peter Ulrich, Jay Tibbitts, Andreas Baumann, Wolfgang F. Richter, Sven Kronenberg, Simon Chivers, Guenter Blaich, Lolke de Haan, Robert Caldwell
Publikováno v:
Regulatory Toxicology and Pharmacology. 80:S1-S14
New challenges and opportunities in nonclinical safety testing of biotherapeutics were presented and discussed at the 5th European BioSafe Annual General Membership meeting in November 2015 in Ludwigshafen. This article summarizes the presentations a
Autor:
Jürgen Bachl, Michael Hettich, Bruno Gomes, Maria Amann, Greg Dugan, Mark A. Cline, Sai Kumar Solingapuram Kiran, Wouter H. P. Driessen, Estelle Marrer-Berger, Jason M. Grayson, David L. Caudell, Volker Teichgräber, Flavio Crameri, Christina Claus, Christian Klein, Oliver Krieter, Stefan Evers, Dietrich Tuerck, Maurizio Ceppi
Publikováno v:
Cancer Research. 80:6135-6135
The translatability of mouse models for the clinical development of cancer immunotherapies remains limited because of substantial differences between the murine and the human immune systems, as well as dissimilarities in the tumor biology. Non-human
Autor:
Sabine Lang, Guus A.M.S. van Dongen, Oliver Ast, Tapan K. Nayak, Heather Hinton, Erwin van Puijenbroek, Hofer Thomas U, Michaele Roemmele, Peter Brünker, Ingo H. Gorr, Samuel Moser, Marije Bolijn, Sebastian Neumann, Jörg Benz, Flavio Crameri, Ekkehard Moessner, Martine Stihle, Danielle J. Vugts, Maria Cristina De Vera Mudry, Marina Bacac, David Wittig, Pablo Umana, Inja Waldhauer, Jose Saro, Anne Freimoser-Grundschober, Christian Klein, Claire Dunn, Stefan Evers, Nicolini Valeria G, Christian Gerdes
Publikováno v:
OncoImmunology, 6(3):e1277306. Landes Bioscience
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
OncoImmunology, Vol 6, Iss 3 (2017)
Klein, C, Waldhauer, I, Nicolini, V G, Freimoser-Grundschober, A, Nayak, T, Vugts, D J, Dunn, C, Bolijn, M, Benz, J, Stihle, M, Lang, S, Roemmele, M, Hofer, T, van Puijenbroek, E, Wittig, D, Moser, S, Ast, O, Brünker, P, Gorr, I H, Neumann, S, de Vera Mudry, M C, Hinton, H, Crameri, F, Saro, J, Evers, S, Gerdes, C, Bacac, M, van Dongen, G, Moessner, E & Umaña, P 2017, ' Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy : Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines ', OncoImmunology, vol. 6, no. 3, e1277306 . https://doi.org/10.1080/2162402X.2016.1277306
Oncoimmunology
We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f94cba31a29a6556c5c8828f4eec574f
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf
https://research.vumc.nl/en/publications/c3698f17-7a30-4c34-908d-56ad5f91e5cf
Publikováno v:
The FASEB Journal. 29
Introduction: Carnitine palmitoyltransferases (CPT1 and 2) regulate the rate of fatty acid oxidation through intake of long-chain fatty acids (LCFA) into mitochondria. Inhibition of CPT can reduce ...
Autor:
David A. Eichler, Bernhard Schläppi, John Wood, Flavio Crameri, Robin A. Seymour, Barbara Lenz, Hugh Wiltshire
Publikováno v:
Toxicologic Pathology. 33:356-364
An unexpected dose related increase in oral squamous cell carcinomas was observed in a standard 2-year carcinogenicity study with a novel calcium channel blocker, in which Wistar rats received daily doses of 0, 1.5, 7, 20, or 40 mg/kg of the compound
Autor:
Silvio Albertini, Laura Suter, Flavio Crameri, Michael Fountoulakis, Maria-Christina de Vera, Rodolfo Gasser, Franziska Boess
Publikováno v:
Toxicology and applied pharmacology. 183(1)
The gene and protein expression changes after exposure to a toxic compound might help elucidate its mechanism of action. In this paper we investigated the effect of carbon tetrachloride (CCl4) on the gene and protein expression in rat livers. Adult W
Autor:
Michael Winter, Flavio Crameri, Peter Berndt, Laura Suter, Silvio Albertini, Michael Fountoulakis, Urs A. Boelsterli
Publikováno v:
Electrophoresis. 21(11)
Overdose of acetaminophen (APAP) causes acute hepatotoxicity in rodents and man. The mechanism underlying APAP-induced liver injury remains unclear, but experimental evidence strongly suggests that activation of APAP and subsequent formation of prote